| Demographics . | No. (%) . |
|---|---|
| Mean age (range), y | 59 (21-77) |
| Female | 20 (52.6) |
| Tumor site | |
| Colorectal | 5 (13.1) |
| HNSCC | 5 (13.1) |
| Breast | 5 (13.1) |
| Othera | 23 (60.5) |
| Treatment | |
| Involves anti-PD-1/PD-L1 antibodies | 33 (86.8) |
| Combination trial | 31 (81.6) |
| Prior anti-PD-1/PD-L1 antibodies | 9 (23.7) |
| Response rate by RECIST v1.1 | |
| Partial response | 3 (7.8) |
| Stable disease | 11 (28.9) |
| Progressive disease | 24 (63.1) |
| Demographics . | No. (%) . |
|---|---|
| Mean age (range), y | 59 (21-77) |
| Female | 20 (52.6) |
| Tumor site | |
| Colorectal | 5 (13.1) |
| HNSCC | 5 (13.1) |
| Breast | 5 (13.1) |
| Othera | 23 (60.5) |
| Treatment | |
| Involves anti-PD-1/PD-L1 antibodies | 33 (86.8) |
| Combination trial | 31 (81.6) |
| Prior anti-PD-1/PD-L1 antibodies | 9 (23.7) |
| Response rate by RECIST v1.1 | |
| Partial response | 3 (7.8) |
| Stable disease | 11 (28.9) |
| Progressive disease | 24 (63.1) |
Others (grouped): esophagus; ovary; neuroendocrine tumor; cholangiocarcinoma; renal cell carcinoma; melanoma; anal squamous cell carcinoma; endometrial; mesothelioma; prostate; pancreas; sarcoma; germ cell tumor; small bowel; small cell lung cancer. HNSCC = head and neck squamous cell carcinoma; RECIST = response evaluation criteria in solid tumors.
| Demographics . | No. (%) . |
|---|---|
| Mean age (range), y | 59 (21-77) |
| Female | 20 (52.6) |
| Tumor site | |
| Colorectal | 5 (13.1) |
| HNSCC | 5 (13.1) |
| Breast | 5 (13.1) |
| Othera | 23 (60.5) |
| Treatment | |
| Involves anti-PD-1/PD-L1 antibodies | 33 (86.8) |
| Combination trial | 31 (81.6) |
| Prior anti-PD-1/PD-L1 antibodies | 9 (23.7) |
| Response rate by RECIST v1.1 | |
| Partial response | 3 (7.8) |
| Stable disease | 11 (28.9) |
| Progressive disease | 24 (63.1) |
| Demographics . | No. (%) . |
|---|---|
| Mean age (range), y | 59 (21-77) |
| Female | 20 (52.6) |
| Tumor site | |
| Colorectal | 5 (13.1) |
| HNSCC | 5 (13.1) |
| Breast | 5 (13.1) |
| Othera | 23 (60.5) |
| Treatment | |
| Involves anti-PD-1/PD-L1 antibodies | 33 (86.8) |
| Combination trial | 31 (81.6) |
| Prior anti-PD-1/PD-L1 antibodies | 9 (23.7) |
| Response rate by RECIST v1.1 | |
| Partial response | 3 (7.8) |
| Stable disease | 11 (28.9) |
| Progressive disease | 24 (63.1) |
Others (grouped): esophagus; ovary; neuroendocrine tumor; cholangiocarcinoma; renal cell carcinoma; melanoma; anal squamous cell carcinoma; endometrial; mesothelioma; prostate; pancreas; sarcoma; germ cell tumor; small bowel; small cell lung cancer. HNSCC = head and neck squamous cell carcinoma; RECIST = response evaluation criteria in solid tumors.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
